An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up?
AstraZeneca is in a hurry.
We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.
That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
